Business Wire

FORRESTER

18.9.2023 12:01:29 CEST | Business Wire | Press release

Share
Forrester Announces Full Conference Agenda For Technology & Innovation EMEA 2023

Forrester (Nasdaq: FORR) today announced the full conference agenda for Technology & Innovation EMEA, held in London and digitally 12–13 October 2023. As technology finds its way into every function of business, the role of the technology organisation and leader has changed. To stay competitive in today’s business environment, tech leaders need to anticipate the future needs of customers and align critical business capabilities — all underpinned by technology — to help their companies capture value and drive business growth.

At this year’s Technology & Innovation EMEA, chief information officers, chief technology officers, chief digital officers, and other technology leaders will learn best practices to help their organisations prioritise the right decisions, accelerate time to value, and deliver successful outcomes for customers and employees. They will also learn how to leverage emerging technologies such as generative AI to drive innovation and improve efficiency.

The event will include several guest keynote speakers, including noted author, Columbia Business School professor, and founder of the Mentora Institute, Hitendra Wadhwa, and Lloyds Banking Group head of digital delivery and strategy, Mitchell Nova, who will share how new technologies can enhance existing architecture platforms to spark transformation. Technology & Innovation EMEA will also honour EMEA recipients of Forrester’s Technology Awards, which recognise organisations that have successfully implemented technology strategies that are outcome-driven and customer-obsessed to accelerate business growth.

Noteworthy keynotes and sessions include:

  • Technology’s Role In Driving The Customer-Obsessed Growth Engine. This keynote discusses how tech executives must work with key stakeholders in their organisation to develop strategies that drive customer value and enable, create, and amplify growth.
  • Predictions 2024. Generative AI is exponentially gaining momentum within the future of work, editorial, customer experience, and code writing. In this keynote, learn about the next frontier of innovation threats, advantages, and opportunities in the year ahead.
  • The Metaverse Hype Is Over. The Real Work Continues. The metaverse does not exist yet, but precursors do, in consumer- and employee-facing scenarios. This session will discuss how companies are reaching consumers in virtual worlds and how they can make use of new environments for employee onboarding, training, and collaboration.
  • Fact Vs. Fiction: When Should You Invest In The Next Shiny Thing? Generative AI already has a key place in the enterprise technology portfolio. This session reveals the current state of the latest emerging technologies, what this means for enterprises, and the lessons that leaders can learn from early adopters of these technologies.
  • Digital Leaders Must Become Bolder To Plug Skill Gaps. Every organisation is facing skill gaps when tackling their broader digital transformation initiative. This session will discuss how most European business leaders have difficulty finding the digital talent they need and what they can do to combat this challenge.

“Regardless of the economic climate, technology and innovation is essential to driving business growth,” said Pascal Matzke, event host and VP, research director at Forrester. “Since CIOs and the IT organisation have the broadest span of control and visibility across business, processes, and data systems, they are in the best position to see the big picture and help prioritise initiatives that drive growth. At Technology & Innovation EMEA, tech leaders will learn how to develop resilient, adaptive, and creative strategies that inspire innovation, improve customer experiences, and supercharge business outcomes.”

In-person attendees will experience facilitated discussions, consulting workshops, and special programmes, including the Women’s Leadership Forum; the Executive Leadership Exchange, an exclusive programme targeted at C-level leaders; and several diversity and inclusion sessions. Digital attendees will have access to all conference sessions and sponsors via the event platform.

Resources:

  • Register to attend Forrester’s Technology & Innovation EMEA 2023 conference.
  • View the full agenda and speakers for Technology & Innovation EMEA 2023.
  • Learn about Technology & Innovation EMEA sponsorship opportunities.
  • Follow @Forrester and #ForrTech for updates.

About Forrester

Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the centre of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; 70 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918409305/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye